• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Merz + Co. and Forest Laboratories announce US Market Agreement for Memantine for Dementia, Neuropathic Pain and other CNS Indications

Frankfurt am Main/New York, 29.06.2000

Merz + Co. and Forest Laboratories announced today that they have entered into a license and cooperation agreement for the further development of Merz’ compound memantine for Alzheimer’s disease (AD), neuropathic pain and other central nervous system (CNS) indications.

“Merz is excited about this new partnership with Forest Laboratories, a highly respected marketer of Central Nervous System (CNS) pharmaceuticals,” said Dr. Jochen Hückmann, president of Merz + Co. “This agreement is in line with Merz’ firm commitment to develop novel, new CNS compounds for the U.S. and European markets and especially to develop memantine to better help patients suffering from dementia.”

“We believe memantine is a immensely useful and versatile drug which will be very helpful for many people,” said Howard Solomon, chairman and CEO of Forest Laboratories. “We are delighted to enter into this relationship with Merz which has a leading research program in CNS and particularly in the field of N-methyl-D-aspartate (NMDA) antagonists. We plan to discuss with the FDA the submission of a New Drug Application (NDA) for dementia and neuropathic pain indications.”

Merz currently markets memantine in Germany for dementia, the leading prescription product in this therapeutic area in Germany. Merz has developed memantine for a number of CNS applications and several patents cover memantine for different CNS indications.

Merz + Co., a pharmaceutical company, is a leading company in central nervous system research in Germany. Merz develops, manufactures and markets pharmaceutical products worldwide.

Forest Laboratories, Inc., headquartered in New York, is an international pharmaceutical manufacturer and marketer specializing in proprietary cardiovascular and CNS products. Forest Laboratories common stock is traded on the New York Stock Exchange (NYSE: FRX, www.forestlabs.com).

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s